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An endogenous substance which specifically displaces clonidine, yohimbine and rauwolscine from rat 
brain cyz-adrenergic receptors, has been isolated. The new compound, designed clonidine-displacing- 
substance (CDS), has been partially purified by ion exchange chromatography, zone electrophoresis and 
high performance liquid chromatography (HPLC). CDS binds specifically to cYz-adrenergic receptors by 
competing with either cuz-adrenergic agonists or cYz-antagonists, but has no effect on the specific binding 
of [3H]prazosin to cYr-adrenergic receptors in rat brain membranes. In the course of isolation, CDS was 
shown to be neither the endogenous neurotransmitter (- )norepinephrine (NE) nor the guanyl nucleotide 
GTP which lowers the specific binding of cYz-agonists to the cus-adrenergic receptors. 
Clonidine cYrAdrenergic receptor Yohimbine 
1. INTRODUCTION oblongata [lo], prompted us to look for an en- 
dogenous clonidine-like substance in the brain. 
The wide-spread interest in m-adrenergic 
agonists is mostly due to their clinical application 
as antihypertensive drugs. Clonidine, guanabenz, 
guanadrel, labaz, guanoxan and tramazoline are 
but a few representatives of numerous imidazoline 
and guanido-containing az-agonists (review 
[l-4]). Their potent antihypertensive activity 
results from stimulation of cuz-adrenergic receptors 
in the central nervous system (CNS). Clonidine is 
an imidazoline which is defined as being exclusive- 
ly an cY2-agonist, and it is shown to compete with 
NE, the endogenous &z-agonist [5,6]. LY- 
Methyldopa, considered to be among the most 
specific a2-agonists [7-91, was recently shown to 
be ineffective as a hypotensive agent at the nucleus 
reticularis lateralis (NRL) which is the main site of 
hypotensive action of clonidine in the medulla 
oblongata [lO,ll]. The abundance of guanido- 
containing substances in the spinal fluid and in the 
CNS (guanido acetic acid, guanido glutaric acid, 
guanido succinic acid, etc.) [12], as well as the ex- 
istence of a structure-activity relationship for im- 
idazoline structure in the NRL at the medulla 
2. EXPERIMENTAL 
2.1. Chemicals 
[3H]Clonidine (25.5 Ci/mmol; Ci = 3.7 x 10” 
becquerels), [3H]prazosin (40 Ci/mmol), [3H]yo- 
himbine (80 Ci/mmol), [3H]NE (24.6 Ci/mmol) 
and [3H]rauwolscine (79 Ci/mmol) were purchas- 
ed from New England Nuclear. The following were 
generous gifts: phentolamine, from Ciba Geigy, 
and clonidine, from Boehringer Ingelheim. (-)NE 
was purchased from Sigma. Other chemicals and 
biochemicals were of the highest purity available. 
In high performance liquid chromatography 
(HPLC) studies, the water was distilled 3 times and 
the solvents were of HPLC grade. 
2.2. Binding of [3HJclonidine, f3HJyohimbine, 
[3HJrauwolscine and [3HJprazosin to rat brain 
PZ membranes 
The membrane preparation and the binding 
assays were carried out essentially as in [13]. 
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2.2.1. cYz-Adrenergic receptors 
Binding to az-adrenergic receptors was 
evaluated in an assay volume of 0.3 ml, containing 
200-3OOpg membrane protein from rat brain, in 
50 mM Tris-HCI (pH 7.5), using either 3-5 nm 
[3H]clonidine, 1 nM [3H]yohimbine or [3H]rau- 
wolscine, respectively. Specific binding which was 
70-80% in [3H]clonidine binding, 70% in [3H]yo- 
himbine binding and 60% in [3H]rauwolscine bind- 
ing, was determined by subtracting non-specific 
binding at 10 PM NE [13] from total binding. 
2.2.2. ai-Adrenergic receptors 
The same binding procedure as described above 
for the cuz-adrenergic receptors was followed, with 
1 nM [3H]prazosin, an cur-specific radioligand. 
Phentolamine (33 ,uM) was used to determine non- 
specific binding. 
2.3. Protein assay 
Protein concentration determinations were car- 
ried out as in [14], using bovine serum albumin as 
the standard. 
2.4. HPLC studies 
These studies were performed by reverse-phase 
liquid chromatography using RP-8 or RP-18 col- 
umns (lOrm, 4.6 x 250 mm, Alltech, IL). 
3. RESULTS 
3.1. Isolation and partial purification of an 
endogenous compound which binds to 
a_?-adrenergic receptors 
During the purification procedure, at each step 
samples were withdrawn and their biological ac- 
tivity as well as the yield of isolation were deter- 
mined. All activity measurements were carried out 
by displacement studies of [3H]clonidine from rat 
brain Pz-membrane preparations, using 10 PM 
(-)NE as a reference for non-specific binding. 
One unit of activity is defined as the amount need- 
ed to displace 50% of specifically bound 
[3H]clonidine under standard conditions (3.5 nM 
[3H]clonidine and 250 pg protein per assay, 40 min 
at 25°C). 
3.1.1. Step 1: crude methanolic extract 
Calf brains (-300 g wet wt, after removal of the 
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cerebellum) were excised into small pieces 
(l-3 cm) and placed into 3 vols (w/v) of 10 mM 
Tris-HCl buffer (pH 7.7) at 4°C. The slices were 
subjected to 25 s of homogenization in Polytrone, 
followed by centrifugation at 100000 x g for 
30 min at 4°C. The pellet was discarded and the 
supernatant (-60% of the total volume) was boiled 
for 15 min over a water bath. After cooling, the 
boiled soup was centrifuged at 100000 x g for 
15 min at 4°C. Extraction of the dry lyophilizate 
(2.9 g, -1% yield; yields varied from 1.2-0.9% of 
the brains’ wet wt) was performed with 20 vols 
methanol. The methanolic extract contains an 
average of 3000 units/300 g (an average of 1500 + 
100 units/l50 g wet wt). 
3.1.2. Step 2: DEAE-Sephacel column 
The crude methanolic extract was chromatog- 
raphed on a DEAE-Sephacel column (1.25 cm2 x 
20 cm). The activity was eluted at 0.11-o. 14 M in 
a gradient of 0.0-0.25 M ammonium bicarbonate. 
L3H]NE was included in one of the column runs 
and eluted with the water washings prior to the in- 
itiation of the gradient. 
3.1.3. Step 3: zone electrophoresis 
Column electrophoresis in agarose suspension 
(0.18%, w/v) was carried out as in [15]. The activi- 
ty eluted from DEAE-Sephacel (not exceeding 
20 mg dry wt) was dissolved in 0.6 ml of the 
agarose suspension in 0.01 M ammonium bicar- 
bonate (pH 8.1) and applied to the column (0.9 x 
65 cm). The electrophoresis was carried out for 
20 h at 490 V at a current of 4 mA. Samples of 
0.6 ml were taken out by suction from the top. The 
samples were assayed for activity and their absor- 
bance at 275 nm was recorded (fig.1). Ninety to 
100% of the biological activity was recovered. 
3.1.4. Step 4: HPLC 
Lyophilized samples, after zone electrophoresis, 
were injected into a reverse-phase column and 
eluted from it with n-propanol (0-SOcr/o) for 1 h in 
0.1% TFA. The biological activity was eluted with 
36-42% n-propanol (fractions 21-23) (fig.2). The 
80-90% of the recovered biological activity was 
ninhydrin and fluorescamine negative. GTP, in- 
corporated in one of the runs, was not retained on 
the column. Displacement of specifically bound 
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Fig. 1. Column electrophoresis in agarose suspension. 
Extracted CDS activity from DEAE-Sephacel column 
(lo-20 mg dry powder), dissolved in 0.6 ml of 0.18% 
agarose suspension of 0.01 M ammonium bicarbonate 
(pH 8.4), was applied to the column (start). An electrical 
current of 4 mA was applied at 490 V for 20 h. The 
activity was determined on aliquots (l-3%) of the 
supernatant after centrifugation of 0.6 ml withdrawn 
samples (15000 x g, 2 min) (M). Absorbance at 
275 nm was determined (m). 
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Fig.2. HPLC of the activity eluted from zone 
electrophoresis run. The lyophilizate preparation (100 
units after zone electrophoresis) was applied to the 
HPLC column (size 4.1 mm interior diameter x 25 cm) 
and eluted at a rate of 0.8 ml/min in a linear gradient of 
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Fig.3. Displacement of specifically bound [3H]clonidine 
in rat brain membranes by CDS (HPLC fraction). 
Displacement of [‘Hlclonidine from rat brain membrane 
was performed as described in section 2. Aliquots of 
CDS (0.5-20~1) were added to a binding mixture 
containing 8.8 nM [3H]clonidine, 150 /rg protein 
membrane, in a final volume of 0.25 ml. Non-specific 
binding was determined in the presence of 10pM 
(- )NE. Total binding is 144 fmol/mg protein and non- 
specific binding is 62 fmol/mg protein: 
Table 1 
Steps in the purification of CDS: calculations of percent 
yield based on weight 
Purification step 
Calf brain 
Methanolic extract 
DEAE-Sephacel 
Zone electrophoresis’ 
Weight (g) Yield (070) 
300 (wet wt) 100 
3.0 f 0.2 1.0 It 0.2 
0.6 f 0.2a 0.2 f 0.06 
not detectableb 
a Most probably contains NI&HCOs 
b Amount too low to be weighed 
[‘Hlclonidine in rat brain membranes by CDS 
(HPLC fraction) is presented in fig.3. 
0.1% TFA and O-50% n-propanol. Absorbance was 
detected by Instrumentation Specialists Co., model 
1840, recorder. Activity of 5% of each fraction after 
lyophilization was determined. CDS eluted at 36-42070 
n-propanol. Control runs show an identical pattern 
(marked by dotted line) of the absorbance at 220 nm but 
without any activity. 
3.2. Absence of cupadrenergic activity 
One and 2 units of CDS activity did not affect 
the binding of 1 mM [3H]prazosin to rat brain. 
Phentolamine (33 &I) and NE (33 PM) were used 
for the determination of non-specific binding 
(fig.4). 
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Fig.4. The effect of CDS on cur-adrenergic receptors. 
Displacement of [3H]prazosin from rat brain 
membranes was performed as described in section 2. 
One unit (25 pi) and 2 units (50~1) of CDS were added 
to the binding mixture, and the effect of specific binding 
was determined in the presence of either 33 ,uM 
phentolamine or 33 /IM (- )NE. 
4. DISCUSSION 
A new activity (CDS) is purified in a four-step 
procedure: methanolic extraction, ion exchange 
chromatography (DEAE), zone electrophoresis 
and HPLC. Although similar activity was obtained 
from rat brain, due to the small quantities 
available, the studies were shifted to calf brain. 
The endogenous compound (CDS) extensively 
purified from calf brain has cut-adrenergic proper- 
ties. After HPLC, CDS is obtained in minute 
amounts which are not detectable by weight and 
are insufficient for determination of molecular 
mass or for carrying out NMR analysis or chemical 
analysis. Scaling up the production of the com- 
pound will be necessary before a final structure 
may be determined. 
The new substance displaces specifically bound 
[3H]clonidine, [3H]yohimbine and j3H]rauwolscine 
in rat brain membranes. These are three specific 
cua-adrenergic ligands which are commonly used to 
probe cuz-adrenergic receptors. It is therefore sug- 
gested that the new activity which can specifically 
displace these ligands might have some structural 
resemblance that permits the interaction at the 
cuz-adrenergic sites. No effect on the specific bind- 
ing to or-adrenergic receptors was observed using 
[3H]prazosin, a specific or-antagonist. CDS has 
negative ninhydrin and negative fluorescamine 
reactions. 
The possibility of another endogenous ligand 
with adrenergic properties, present in the brain, 
can meet some of the difficulties to explain the ef- 
fects of adrenergic drugs on arterial pressure [16] 
or the insensitivity of junctional receptors to phen- 
tolamine or prazosin in smooth muscle organ [ 171. 
Our present effort is directed toward scaling up the 
production of the compound for determination of 
its chemical structure, and expanding its biological 
characteristics by application of CDS in elec- 
trophysiological studies into specific nuclei in the 
brain. 
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